-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Kura Oncology, Lowers Price Target to $20

Benzinga·01/13/2026 16:04:52
Listen to the news
Leerink Partners maintains Kura Oncology (NASDAQ:KURA) with a Outperform and lowers the price target from $25 to $20.